stockrowAstraZeneca PLC
AZN Healthcare Drug Manufacturers General
AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024.
- Revenue
- +6.70%
- EPS
- +22.5%
- Free cash flow
- +1.99%
- Total debt
- +1.75%
Quarter to September 2026, against a year earlier
Follow AZN
Alert me
AstraZeneca PLC (AZN) Revenue
AstraZeneca PLC's revenue for fiscal 2025 was $58.7B, up 8.63% from $54.1B in fiscal 2024. Over the twelve months to 30 September 2026 it was $62.4B. Over the past ten years it has ranged from $22.1B (fiscal 2018) to $58.7B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 7 consecutive fiscal years. AstraZeneca PLC ranks 6th of 18 Drug Manufacturers General companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $58.7B | 8.63% |
| FY2024 | $54.1B | 18.03% |
| FY2023 | $45.8B | 3.29% |
| FY2022 | $44.4B | 18.53% |
| FY2021 | $37.4B | 40.58% |
| FY2020 | $26.6B | 9.16% |
| FY2019 | $24.4B | 10.38% |
| FY2018 | $22.1B | (1.67%) |
| FY2017 | $22.5B | (2.33%) |
| FY2016 | $23.0B | (6.90%) |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $16.2B | 5.36% |
| Jun 2026 | $15.4B | 0.63% |
| Mar 2026 | $15.3B | (1.39%) |
| Dec 2025 | $15.5B | 2.05% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| MRK Merck & Co., Inc. compare | $67.4B |
| ABBV AbbVie Inc. compare | $66.0B |
| PFE Pfizer Inc. compare | $63.6B |
| AZN AstraZeneca PLC | $62.4B |
| NVS Novartis AG compare | $57.4B |
| NVO Novo Nordisk A/S compare | $51.5B |
| BMY Bristol Myers Squibb Company compare | $50.0B |
| AMGN Amgen Inc. compare | $38.9B |
| GILD Gilead Sciences, Inc. compare | $31.0B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on AZN
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement